Related Experiment Video
Updated: Aug 29, 2026

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
Red wine and red wine polyphenolic compounds but not alcohol inhibit ADP-induced platelet aggregation
D.W. De Lange1, P.H. Van Golden, W.L.G. Scholman
1Department of Internal Medicine, Meander Medical Center, PO Box 1502, 3800 BM Amersfoort, The Netherlands.
Insights
Red wine polyphenols, not alcohol, inhibit platelet aggregation. This effect, seen only at very high red wine concentrations, may not be clinically relevant for moderate drinkers.
Area of Science:
- Cardiovascular Health
- Pharmacology
- Nutrition Science
Background:
- Moderate alcohol intake is linked to reduced cardiovascular disease (CVD) risk, particularly coronary heart disease (CHD).
- Red wine's polyphenols are hypothesized to offer superior cardioprotection compared to other alcoholic beverages.
- Inhibition of platelet aggregation is a potential mechanism for red wine's cardiovascular benefits.
Purpose of the Study:
- To investigate the direct impact of alcohol and red wine polyphenols on platelet aggregation.
- To differentiate the effects of alcohol versus polyphenolic compounds in red wine on platelet function.
Main Methods:
- Blood platelets were treated with varying concentrations of red wine, red wine polyphenolic extract, or alcohol.
- Platelet aggregation was induced using adenosine diphosphate (ADP) and measured using an aggregometer.
- Results were compared against a control group treated with a saline solution.
Main Results:
- Alcohol, up to 0.24% concentration, showed no significant inhibition of ADP-induced platelet aggregation in vitro.
- Red wine polyphenolic extract demonstrated a dose-dependent and significant inhibition of platelet aggregation.
- Red wine itself only inhibited platelet aggregation at very high concentrations (0.24% and 0.48% alcohol).
Conclusions:
- The inhibitory effect of red wine on platelet aggregation is attributed to its polyphenolic compounds, not alcohol.
- Alcohol lacks a direct inhibitory effect on platelet aggregation within the tested concentrations.
- The observed effects at high concentrations suggest limited clinical relevance for moderate red wine consumption regarding direct platelet inhibition.
Abstract:
Background: Moderate alcohol consumption reduces the risk of cardiovascular diseases, especially coronary heart disease (CHD). Because of the presence of polyphenols in red wine, this type of beverage may be superior to other alcoholic drinks in the prevention of CHD. Inhibition of platelet aggregation is thought to be one of the mechanisms underlying this favorable effect. The present study analyzes the direct effect of alcohol and red wine polyphenols on platelet aggregation. Methods: Unfractionated red wine, a red wine polyphenolic extract, and alcohol were added in different concentrations to a standardized quantity of blood platelets 2 min before aggregation was induced by different concentrations of ADP. Aggregation was measured in an aggregometer and results were compared to a control 0.9% NaCl solution. Results: Alcohol in concentrations up to 0.24 percent did not inhibit platelet aggregation in vitro initiated with ADP The polyphenolic red wine extract inhibited aggregation dose-dependently and significantly from concentrations of 45 mg/l ( [Formula: see text] ) or more. Red wine only inhibited platelet aggregation at very high concentrations ( approximately 0.24 and 0.48 alcohol%). Conclusions: Consumption of red wine has an inhibitory effect on platelet aggregation, which is caused by the polyphenolic compounds in the wine. Alcohol itself does not have a direct inhibitory effect within a range up to 0.24 percent. Since this effect is only observed at very high concentrations, it is unlikely to be of clinical relevance in a moderate drinking pattern. The results do not exclude platelet inhibition by wine in vivo. However, this must be related to metabolic changes rather than to direct blockade.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Drugs Affecting Neurotransmitter Synthesis
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...

